Oct. 27, 2026

Mathison Centre Celebrates First Graduates of Psychiatric Drug Development Program

The inaugural program gives medical students practical experience in psychiatric drug development and clinical research.

Clinical trials are the foundation of medical innovation, ensuring that new therapies are both safe and effective before they reach patients. As modern medicine becomes increasingly complex, physicians involved in clinical research require specialized training beyond the traditional medical curriculum. This need is particularly evident in psychiatry, where mental illness remains a leading contributor to the global burden of disease. Despite this need, relatively few new psychiatric medications have emerged in recent decades.

To address these challenges, the Mathison Centre for Mental Health Research & Education launched its inaugural Clinical Leadership Track in Psychiatric Drug Development for medical students at the Cumming School of Medicine during the 2025–2026 academic year. The annual program introduces future physician leaders to the full spectrum of psychiatric drug development while providing hands-on experience in clinical research. 

Dr. Matthew Hill, PhD, Director, Mathison Centre, emphasizes that bringing people together across disciplines is central to the Centre’s mission:
 
“Improving mental health requires us to bring together people with different expertise, perspectives, and experiences and create opportunities for them to work toward the same goal,” says Dr. Hill. 

“That work starts early. When medical students are given the chance to engage directly with mental health research and drug development, they are exposed to a field with enormous potential for innovation and to the people working to make that innovation possible. We hope that some of these students will become the next generation of innovators and physician-scientists who push the field forward and shape the future of mental health care. That is exactly the kind of connection we want the Mathison Centre to foster.”

First cohort of grads

From R to L: Valerie Taylor, MD, PhD, Shanine van Rooijen, Marc D. Ferger, MD (Medical Course Director), Lea Love, Linda Chen, Areeba Tarique, Jacob Xiang, Justine Beghin, Tom Ding, Theresa Brown, Govind Peringod, and Gavin Petrie, PhD.

Through bi-weekly seminars led by experts from the Hotchkiss Brain Institute, the Mathison Centre, and industry partners, students explored every stage of the drug discovery and development process. Topics included Good Clinical Practice, psychiatric clinical trial design, safety and efficacy in psychopharmacology, regulatory aspects of drug development, and emerging innovations such as biomarker-guided precision psychiatry. A central theme was translational psychiatry, highlighting how collaboration between pre-clinical scientists and clinicians can accelerate treatment development.

Beyond the classroom, students gained valuable practical experience. They visited pre-clinical research labs to learn about disease models and cutting-edge neuroscience techniques providing insight into the biological mechanisms underlying psychiatric disorders. An integral component of the program was the opportunity to apply theoretical knowledge in real-world clinical research. Under the supervision of experienced clinical investigators, participants contributed to ongoing psychiatric clinical trials at the Psychedelic and Cannabinoid Therapeutics (PaCT) Lab, directed by Dr. Leah Mayo, PhD.

“Developing innovative approaches to mental health requires collaboration across disciplines,” says Dr. Mayo, the Parker Psychedelic Research Chair in the Department of Psychiatry, who leads multiple clinical trials. 

“To be successful, these teams must be able to ‘speak the same language,’ though much of this knowledge is not covered in current curriculums. Drs. Petrie and Ferger have laid the groundwork for the Mathison Centre to lead in training a new wave of physician-scientists that can critically advance novel mental health solutions”

The inaugural program ran from September 2025 to June 2026, bringing together first-year medical students with faculty, trainees and research staff from the Hotchkiss Brain Institute, the Mathison Centre for Mental Health Research and Education, and the Calgary Centre for Clinical Research.

The program was led by Scientific Course Director Dr. Gavin Petrie, PhD, and Medical Course Director Dr. Marc D. Ferger, MD. Contributors included Dr. Matthew Hill, PhD, Dr. Leah Mayo, PhD, Dr. Ryann Tansey, PhD, Dr. S. Gibson Cook, PhD, and Jenna Dobry, whose expertise and mentorship helped shape the students' learning experience.

Building on the inaugural year, the program will welcome a new cohort of first-year medical students in the 2026–2027 academic year.